Singapore-based NMT Pharmaceuticals has signed a licensing agreement with U.S. pharma firm CAO Pharmaceuticals for an exclusive worldwide license right to further develop and market an anti-cancer drug CZ-48 co-developed by CAO Pharma and NMT Pharma. NMT Pharma has completed due diligence of the CZ-48 drug for cancer treatment in major markets. “This is a new milestone to expand our business from drug delivery and contract R&D service to having our own drug pipeline,” said David ...